Top Markets
#1 MowCat MowCat +48.96%
#2 Bermuda Shorts Bermuda Shorts +30.38%
#3 Velvet Velvet +25.38%
#4 Audiera Audiera +22.91%
#5 aPriori aPriori +21.24%
#6 Derive Derive +21.04%
#7 Quack AI Quack AI +19.37%
#8 Biconomy Biconomy +16.01%
#9 Perle Perle +12.23%
#10 Geodnet Geodnet +11.94%
Coin of the day
MowCat MowCat
Settings
Language
ENGLISH
Currency
USD
Theme
Graybug Vision, Inc. Graybug Vision, Inc.

Graybug Vision, Inc.

GRAY
Rank in Stocks #35305
Graybug Vision, Inc. is a biopharmaceutical company currently in its clinical... Graybug Vision, Inc. is a biopharmaceutical company currently in its clinical development phase, dedicated to creating treatments for conditions affecting the eye's retina and optic nerve. Its flagship therapeutic, GB-102, is an injectable microparticle formulation of sunitinib administered directly into the eye. This compound is progressing through Phase I/IIa and IIb clinical trials for wet age-related macular degeneration, while also undergoing Phase IIa trials for diabetic macular edema. Furthermore, GB-102 is being explored as a treatment for diabetic retinopathy. The company's pipeline also includes GB-401, an intraocular implant designed to deliver a beta-adrenergic receptor inhibitor, intended for the management of primary open-angle glaucoma. Initially established as Graybug LLC in 2011, the firm rebranded to Graybug Vision, Inc. in 2016 and is headquartered in Redwood City, California.
Share Price
$2.70
Last synced: 2023-05-17
Market Cap
$4.13M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Graybug Vision, Inc. (GRAY)

Category

Healthcare
Revenue for Graybug Vision, Inc. (GRAY)
Revenue in Aug 2026 TTM: 0
According to Graybug Vision, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Graybug Vision, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE